At close: December 13 at 1:30:36 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,574,843.00
1,394,008.00
767,722.00
500,107.00
717,045.00
Cost of Revenue
854,183.00
775,914.00
361,454.00
240,448.00
366,745.00
Gross Profit
720,660.00
618,094.00
406,268.00
259,659.00
350,300.00
Operating Expense
520,629.00
539,557.00
121,834.00
513,811.00
823,103.00
Operating Income
200,031.00
78,537.00
284,434.00
-254,152.00
-472,803.00
Net Non Operating Interest Income Expense
-143,729.00
-133,426.00
-59,974.00
-101,978.00
-80,714.00
Pretax Income
-397,103.00
-1,113,910.00
-588,914.00
2,595,645.00
5,997,349.00
Tax Provision
30,847.00
-66,261.00
-13,293.00
438,694.00
1,110,897.00
Net Income Common Stockholders
-415,438.00
-995,421.00
102,216.00
1,816,180.00
3,786,465.00
Diluted NI Available to Com Stockholders
-415,438.00
-995,421.00
102,216.00
1,816,180.00
3,786,465.00
Basic EPS
-0.58
-1.50
0.16
2.85
6.12
Diluted EPS
-0.58
-1.50
0.16
2.77
5.93
Basic Average Shares
702,495.61
663,954.00
644,638.00
636,501.38
618,312.73
Diluted Average Shares
702,495.61
663,954.00
644,753.00
668,053.47
642,596.28
Total Expenses
1,374,812.00
1,315,471.00
483,288.00
754,259.00
1,189,848.00
Net Income from Continuing & Discontinued Operation
-415,438.00
-995,421.00
102,216.00
1,816,180.00
3,786,465.00
Normalized Income
-326,008.40
-439,933.12
725,972.39
441,943.66
-930,001.00
Interest Income
92,177.00
66,757.00
22,717.00
769.00
2,627.00
Interest Expense
235,906.00
200,183.00
82,691.00
102,747.00
83,341.00
Net Interest Income
-143,729.00
-133,426.00
-59,974.00
-101,978.00
-80,714.00
EBIT
-161,197.00
-913,727.00
-506,223.00
2,698,392.00
6,080,690.00
EBITDA
-5,292.00
-765,791.00
-473,203.00
2,732,966.00
6,137,828.00
Reconciled Cost of Revenue
854,183.00
775,914.00
361,454.00
240,448.00
366,745.00
Reconciled Depreciation
155,905.00
147,936.00
33,020.00
34,574.00
57,138.00
Net Income from Continuing Operation Net Minority Interest
-415,438.00
-995,421.00
102,216.00
1,816,180.00
3,786,465.00
Total Unusual Items Excluding Goodwill
-111,787.00
-590,621.00
-638,161.00
1,653,737.00
5,788,718.00
Total Unusual Items
-111,787.00
-590,621.00
-638,161.00
1,653,737.00
5,788,718.00
Normalized EBITDA
106,495.00
-175,170.00
164,958.00
1,079,229.00
349,110.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-22,357.40
-35,133.12
-14,404.61
279,500.66
1,072,252.00
12/31/2020 - 12/31/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1795.TW Lotus Pharmaceutical Co., Ltd.
261.00
-1.51%
6472.TW Bora Pharmaceuticals Co., LTD.
751.00
-0.79%
6446.TW PharmaEssentia Corporation
585.00
-1.85%
4114.TWO Synmosa Biopharma Corporation
33.00
-1.49%
4120.TWO Orient EuroPharma Co., Ltd.
48.50
-8.14%
4105.TWO TTY Biopharm Company Limited
73.20
-1.48%
4746.TW Formosa Laboratories, Inc.
71.30
-1.25%
1799.TWO Easywell Biomedicals, Inc.
54.90
0.00%
6785.TWO Alar Pharmaceuticals Inc.
146.00
-2.34%
1789.TW ScinoPharm Taiwan, Ltd.
22.20
-2.20%